Clinical Efficacy of Corticosteroids in the Early Stages of Deterioration in COVID-19 Pneumonia

References

• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi:10.1016/S0140-6736(20)30183-531986264
   PubMed Web of Science ®Google Scholar
• Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `cytokine storm’ in COVID-19. J Inf Secur. 2020;80(6):607–613.
   Google Scholar
• Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature. 2020;583(7816):437–440. doi:10.1038/s41586-020-2355-032434211
   PubMed Web of Science ®Google Scholar
• Sun Y, Dong Y, Wang L, et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: the Beijing experience. J Autoimmun. 2020;112:102473. doi:10.1016/j.jaut.2020.10247332439209
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi:10.1056/NEJMoa200203232109013
   PubMed Web of Science ®Google Scholar
• Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi:10.1016/S2213-2600(20)30079-532105632
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi:10.1016/S0140-6736(20)30566-332171076
   PubMed Web of Science ®Google Scholar
• Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943. doi:10.1001/jamainternmed.2020.099432167524
   PubMed Web of Science ®Google Scholar
• Van Paassen J, Vos JS, Hoekstra EM, Neumann KMI, Boot PC, Arbous SM. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020;24:696. doi:10.1186/s13054-020-03400-933317589
   PubMed Web of Science ®Google Scholar
• Ruan SY, Lin HH, Huang CT, Kuo PH, Wu HD, Yu CJ. Exploring the heterogeneity of effects of corticosteroids on acute respiratory distress syndrome: a systematic review and metaanalysis. Crit Care. 2014;18:R63. doi:10.1186/cc1381924708846
   PubMed Web of Science ®Google Scholar
• World Health Organization. Corticosteroids for COVID-19. Living guidance. Available from: WHO/2019-nCoV/Corticosteroids/2020.1. Accessed 92, 2020.
   Google Scholar
• Sun S, Liu D, Zhang H, Zhang X, Wan B. Effect of different doses and time-courses of corticosteroid treatment in patients with acute respiratory distress syndrome: a meta-analysis. Exp Ther Med. 2019;18:4637–4644. doi:10.3892/etm.2019.816731807150
   PubMed Web of Science ®Google Scholar
• Bösmüller H, Matter M, Fend F, et al. The pulmonary pathology of COVID-19. Virchows Archiv. 2021;478:137–150. doi:10.1007/s00428-021-03053-133604758
   PubMed Web of Science ®Google Scholar
• Shi H, Han X, Zheng C. Evolution of CT manifestations in a patient recovered from 2019 novel coronavirus (2019-nCoV) pneumonia in Wuhan, China. Radiology. 2020;295:200269. doi:10.1148/radiol.2020200269.
   Web of Science ®Google Scholar
• Kooraki S, Hosseiny M, Myers L, Gholamrezanezhad A. Coronavirus (COVID-19) outbreak: what the department of radiology should know. J Am Coll Radiol. 2020;17(4):447–451. doi:10.1016/j.jacr.2020.02.00832092296
   PubMed Web of Science ®Google Scholar
• World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCov) infection is suspected: interim guidance. World Health Organization; 2020. Available from: https://apps:who.int/iris/handie/10665/330893. Accessed 128, 2020.
   Google Scholar
• Meduri GU, Siemieniuk RAC, Ness RA, Seyler SJ. Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS. J Intensive Care. 2018;6:53. doi:10.1186/s40560-018-0321-930155260
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330–1341. doi:10.1001/jama.2020.1702332876694
   PubMed Web of Science ®Google Scholar
• Li H, Yang SG, Gu L, et al. National Influenza A(H1N1)pdm09 clinical investigation group of China. Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia. Influenza Other Respir Viruses. 2017;11(4):345–354. doi:10.1111/irv.1245628464462
   PubMed Web of Science ®Google Scholar
• Fadel R, Morrison AR, Vahia A, et al. Early short course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis. 2020;71(16):2114–2120. doi:10.1093/cid/ciaa601.32427279
   PubMed Web of Science ®Google Scholar
• Fernández-Cruz A, Ruiz-Antorán B, Muñoz-Gómez A, et al. A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality. Antimicrob Agents Chemother. 2020;64:9. doi:10.1128/AAC.01168-20
   Web of Science ®Google Scholar
• Nelson BC, Laracy J, Shoucri S, et al. Clinical outcomes associated with methylprednisolone in mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020.
   Web of Science ®Google Scholar
• Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324(13):1–9. doi:10.1001/jama.2020.16761
   Web of Science ®Google Scholar
• Liu J, Zheng X, Huang Y, et al. Successful use of methylprednisolone for treating severe COVID-19. J Allergy Clin Immunol. 2020;146(2):325–327. doi:10.1016/j.jaci.2020.05.02132479759
   PubMed Web of Science ®Google Scholar
• Fang X, Mei Q, Yang T, et al. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. J Infect. 2020;81(1):147–178. doi:10.1016/j.jinf.2020.03.039
   Web of Science ®Google Scholar
• Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2. Int J Biol Sci. 2020;16(10):1718–1723. doi:10.7150/ijbs.4512332226289
   PubMed Web of Science ®Google Scholar